Cosmos Holdings Inc (COSM)
NASDAQ:COSM
Want to see COSM full AI Analyst Report?
Top Page
Cosmos Holdings
(NASDAQ:COSM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.27
▼(-47.50% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily pressured by weak financial performance—persistent operating losses, thin margins, and ongoing cash burn—despite strong revenue growth and improved leverage. Technicals add further downside risk with a clear downtrend and negative momentum, while valuation support is limited due to negative earnings and no dividend yield.
Positive Factors
Sustained revenue growth
TTM revenue of roughly $69.5M demonstrates durable top-line momentum across the core distribution and related businesses. Consistent revenue growth provides a foundation to scale margins and amortize fixed costs over time, supporting longer-term operational leverage if costs are controlled.
Negative Factors
Persistent operating losses and thin margins
Thin gross margins and sustained deep operating losses show structural profitability weakness. Low margins constrain the company's ability to fund SG&A, R&D, and growth initiatives internally; without material margin expansion, revenue growth alone may not translate into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
TTM revenue of roughly $69.5M demonstrates durable top-line momentum across the core distribution and related businesses. Consistent revenue growth provides a foundation to scale margins and amortize fixed costs over time, supporting longer-term operational leverage if costs are controlled.
Read all positive factors
Cosmos Holdings (COSM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.45M
Dividend YieldN/A
Average Volume (3M)1.18M
Price to Earnings (P/E)―
Beta (1Y)2.01
Revenue Growth29.75%
EPS Growth37.35%
CountryUS
Employees149
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.66
Shares Outstanding54,428,490
10 Day Avg. Volume1,246,475
30 Day Avg. Volume1,183,471
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-1.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$98.60M
Cosmos Holdings Business Overview & Revenue Model
Company Description
Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and o...
How the Company Makes Money
Cosmos Holdings’ revenue model has historically been based on selling healthcare-related products through business-to-business channels. Key revenue streams have included: (1) pharmaceutical and OTC product distribution/wholesaling, where the comp...
Cosmos Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.27M | 54.43M | 53.38M | 50.35M | 56.24M |
| Gross Profit | 7.90M | 4.31M | 4.35M | 5.96M | 8.33M |
| EBITDA | -15.15M | -13.92M | -17.06M | -8.90M | -3.82M |
| Net Income | -19.14M | -16.18M | -18.54M | -13.83M | -7.96M |
Balance Sheet | |||||
| Total Assets | 65.48M | 54.31M | 66.01M | 68.04M | 49.43M |
| Cash, Cash Equivalents and Short-Term Investments | 761.83K | 336.25K | 3.85M | 20.76M | 297.95K |
| Total Debt | 19.97M | 11.82M | 12.42M | 12.03M | 27.12M |
| Total Liabilities | 47.05M | 29.78M | 29.97M | 28.38M | 45.05M |
| Stockholders Equity | 18.42M | 24.53M | 36.04M | 39.66M | 4.38M |
Cash Flow | |||||
| Free Cash Flow | -8.50M | -8.14M | -24.80M | -15.25M | -7.99M |
| Operating Cash Flow | -8.45M | -7.72M | -15.64M | -14.87M | -7.10M |
| Investing Cash Flow | -2.01M | -798.27K | -13.76M | -21.50K | -826.82K |
| Financing Cash Flow | 14.06M | 5.05M | 12.69M | 35.05M | 7.27M |
Cosmos Holdings Technical Analysis
Negative
0.52
Price Trends
0.34
Negative
0.39
Negative
0.60
Negative
Market Momentum
-0.02
Positive
28.84
Positive
6.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.52 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.34, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 28.84 is Positive, neither overbought nor oversold. The STOCH value of 6.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.
Cosmos Holdings Risk Analysis
Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cosmos Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $24.07M | 61.52 | 0.27% | ― | 82.13% | ― | |
49 Neutral | $32.37M | >-0.01 | -4587.82% | ― | -30.75% | -1056.69% | |
49 Neutral | $53.05M | -0.55 | -57.16% | ― | 673.54% | 23.14% | |
47 Neutral | $23.08M | -1.28 | -107.16% | ― | -18.24% | -2264.65% | |
42 Neutral | $14.45M | -1.33 | -63.82% | ― | 29.75% | 37.35% | |
42 Neutral | $929.39K | -0.70 | -404.42% | ― | ― | ― |
* Healthcare Sector Average
COSM
Cosmos Holdings
0.26
-0.19
-42.31%
PRPH
Prophase Labs
0.09
-2.98
-97.07%
RMTI
Rockwell Med
0.81
-0.19
-18.78%
TXMD
TherapeuticsMD
2.11
0.66
45.52%
SCYX
SCYNEXIS
0.71
-0.06
-7.67%
AYTU
Aytu BioScience
2.13
0.11
5.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.